Author:
Schmitz-Dräger Bernd J.,Todenhöfer Tilman,van Rhijn Bas,Pesch Beate,Hudson Mĺiss A.,Chandra Ashish,Ingersoll Molly A.,Kassouf Wassim,Palou Joan,Taylor John,Vlahou Antonia,Behrens Thomas,Critelli Rossana,Grossman H. Barton,Sanchez-Carbayo Marta,Kamat Ashish
Reference38 articles.
1. Schmitz-Dräger BJ, Droller M, Lotan Y, Lokeshwar VB, van Rhijn B, Hemstreet GP, et al. Molecular markers for bladder cancer screening, early diagnosis and surveillance. In: Soloway M, Khoury S, editors. Bladder Cancer: 2nd International Consultation on Bladder Tumors. Paris, France: Editions 2012; 21:171-205
2. Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, et al. The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int 2011;108:546-552
3. Pressler JB, Bayer F, Dixon-Ernst C, Schmitz-Dräger BJ. Screening for bladder cancer using immunocytology—preliminary results from a prospective study in a professionally exposed cohort: the CTP project. 9th Meeting of the International Bladder Cancer Network, Madrid, Spain; 2011.
4. Who should be included in a clinical trial of screening for bladder cancer? a decision analysis of data from the prostate, lung, colorectal and ovarian cancer screening trial;Vickers;Cancer,2013
5. Immunocytology is a strong predictor of bladder cancer presence in patients with asymptomatic hematuria: a multicenter study;Cha;Eur Urol,2012
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献